NEW TREATMENT FOCUSED ON EWING'S SARCOMA
Thursday, December 24, 2009 - 15:33
Dear all..another interesting trial conducted on Ewing's sarcoma - a cancer that affects in or near the bones mainly in teenage boys. The drug under case study is figitumumab which was found to be more effective in treating this sarcoma. The drug must undergo two more phases of testing, however, according to a report published in the Dec. 23 online edition of "The Lancet Oncology".
Patients did experience some side effects, such as deep venous thrombosis, back pain and vomiting in the first phase of clinical trials while some of the patients appeared to respond well to the drug, the study authors noted.
"Figitumumab is well-tolerated and has antitumor activity in Ewing's sarcoma, warranting further investigation in this disease," the researchers wrote. "Our results show that figitumumab can be safe for both adult and pediatric sarcoma patients, and has single-agent antitumor activity in different sarcoma subtypes, including Ewing's sarcoma."
source : latest pharma news @www.drugs.com
- sirisha's blog
- Log in or register to post comments
- 789 reads
Topic:
Comments
zarrinfaria
Thu, 12/24/2009 - 18:19
Permalink
Dear.. A nice blog...where
Dear..
A nice blog...where the trail was conducted...
Regards,
Faria Zarrin
Team: BLOGBUSTERS
My Page :
http://www.pharmainfo.net/zarrinfaria/biography
My Team:
http://www.pharmainfo.net/blog/blogbusters
sirisha
Sat, 12/26/2009 - 03:39
Permalink
dear faria.. thank you for
dear faria..
thank you for the valuable comment..
The details of clinical trials are not disclosed but the result said it was posted in "The lancet oncology"
Sirisha Pingali
http://www.pharmainfo.net/sirisha
vbsishwarya
Fri, 12/25/2009 - 02:45
Permalink
Dear sirisha, Good
Dear sirisha,
Good info........
Why are teenage boys more prone to this attack?
Regards,
sirisha
Sat, 12/26/2009 - 03:33
Permalink
dear aishwarya..thank you
dear aishwarya..
thank you for the valuable comment..
there are some cancers where sex is also major factor for the development of disease. In this case, Males are more prone to the sarcoma. The most common areas in which it occurs are the pelvis, the femur, the humerus, and the ribs.
occurance males : females=1.5:1
Sirisha Pingali
http://www.pharmainfo.net/sirisha
udayasree datla
Fri, 12/25/2009 - 05:41
Permalink
Which pharmaceutical company invented "figitumumab" ?
Hai sirisha,
Informative blog. I never heard of this before. Which pharmaceutical company invented "figitumumab" for the first time ?
sirisha
Sat, 12/26/2009 - 03:29
Permalink
dear udayasree.. thank you
dear udayasree..
thank you for the valuable comment..
figitumumab is a monoclonal antibody used in treatment of various cancers.
It was developed by Pfizer.
Sirisha Pingali
http://www.pharmainfo.net/sirisha
udayasree datla
Sat, 12/26/2009 - 12:55
Permalink
THANK YOU FOR THE INFORMATION
THANK YOU FOR THE INFORMATION SIRISHA.
drgunasakaran1
Tue, 01/12/2010 - 12:16
Permalink
Clinical trial site
Dear Faria,
The clinical trial was conducted in Lombardi Comprehensive Cancer Center, Georgetown University and The Albert Einstein College of Medicine.
drgunasakaran1
Tue, 01/12/2010 - 12:21
Permalink
Figitumumab Clinical trial
Dear Sirisha,
Nice interesting blog. The details of the clinical trial conducted with figitumumab are as follows:
Figitumumab, a fully human IgG2 monoclonal antibody targeting the insulin-like growth factor-1 receptor, was found to be well tolerated and demonstrated antitumor activity in a phase-1 study of adult and pediatric patients with sarcoma or Ewing’s sarcoma.
Years of prior research had already established that the inhibition of IGF-1 receptor would likely be beneficial in patients with Ewing sarcoma. This study was conducted to test figitumumab’s efficacy against sarcoma and Ewing’s sarcoma.
To do this, researchers enrolled patients into two single-stage expansion cohorts between January 2006 and August 2008. Patients received 20 mg/kg figitumumab. The first cohort comprised patients (n=15) with various sarcoma subtypes aged 18 or older; the second cohort, patients (n=14) with refractory Ewing’s sarcoma aged 9 or older. The most common subtype was Ewing’s sarcoma.
One hundred and seventy-seven cycles of treatment were given throughout the study. The researchers reported that adverse events were “mostly mild-to-moderate in severity.”
Grade-3 adverse events were severe in three patients: one with deep vein thrombosis, one with vomiting and one with back pain. In addition, one other patient had grade-3 increases in aspartate aminotransferase and gammaglutamyltransferase concentrations. Cardiotoxicity was not observed.
Twenty-eight patients were evaluable for response to figitumumab. There were two confirmed responses (one pathological response and one partial response). Both of these were in patients with Ewing’s sarcoma. Furthermore, eight other patients, six with Ewing’s sarcoma, had stabilization of disease lasting a minimum of four months.
Source: Olmos D. Lancet Oncol. 2009;doi:10.1016/S1470-2045(09)70354-7
drgunasakaran1
Tue, 01/12/2010 - 12:21
Permalink
human IgG2 monoclonal antibody
Dear Sirisha,
Nice interesting blog. The details of the clinical trial conducted with figitumumab are as follows:
Figitumumab, a fully human IgG2 monoclonal antibody targeting the insulin-like growth factor-1 receptor, was found to be well tolerated and demonstrated antitumor activity in a phase-1 study of adult and pediatric patients with sarcoma or Ewing’s sarcoma.
Years of prior research had already established that the inhibition of IGF-1 receptor would likely be beneficial in patients with Ewing sarcoma. This study was conducted to test figitumumab’s efficacy against sarcoma and Ewing’s sarcoma.
To do this, researchers enrolled patients into two single-stage expansion cohorts between January 2006 and August 2008. Patients received 20 mg/kg figitumumab. The first cohort comprised patients (n=15) with various sarcoma subtypes aged 18 or older; the second cohort, patients (n=14) with refractory Ewing’s sarcoma aged 9 or older. The most common subtype was Ewing’s sarcoma.
One hundred and seventy-seven cycles of treatment were given throughout the study. The researchers reported that adverse events were “mostly mild-to-moderate in severity.”
Grade-3 adverse events were severe in three patients: one with deep vein thrombosis, one with vomiting and one with back pain. In addition, one other patient had grade-3 increases in aspartate aminotransferase and gammaglutamyltransferase concentrations. Cardiotoxicity was not observed.
Twenty-eight patients were evaluable for response to figitumumab. There were two confirmed responses (one pathological response and one partial response). Both of these were in patients with Ewing’s sarcoma. Furthermore, eight other patients, six with Ewing’s sarcoma, had stabilization of disease lasting a minimum of four months.
Source: Olmos D. Lancet Oncol. 2009;doi:10.1016/S1470-2045(09)70354-7